title: Analysis of resistance testing in South Trinidad.
abstract: The introduction of antiretroviral therapy in Trinidad and Tobago in the 1980s has resulted in a decrease in mortality of HIV-infected persons. Poor adherence to antiretroviral therapy (ART) has resulted in the development of multidrug resistant HIV Resistance testing done on 40 samples showed that 64.8% of patients had K103 mutation, 75.6% of patients had M184 mutations and 62% of patients showed resistance to tenofovir suggesting that the K65R mutation was highly likely to be present. There was reduced activity to the protease inhibitors; no resistance was found to the protease inhibitor, darunavir. Thus, there is a need for salvage therapy to be introduced which will result in virologic suppression and potentially stop the spread of multidrug resistant HIV Darunavir a new generation protease inhibitor, is an essential part of salvage therapy and needs to be introduced into the national formulary.
authors.affiliation: Internal Medicine/Infectious Disease, Department of Health Social Services, Tobago House of Assembly, Trinidad and Tobago, West Indies. natduke@yahoo.com
authors.forename: N
authors.initials: N
authors.lastname: Duke
authors.forename: S
authors.initials: S
authors.lastname: Aboh
authors.forename: N
authors.initials: N
authors.lastname: Bosivert
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives / Q000494:pharmacology; D019380:Anti-HIV Agents / Q000494:pharmacology*; D000069454:Darunavir; D018432:Drug Resistance, Multiple; D024882:Drug Resistance, Viral; D015658:HIV Infections / Q000188:drug therapy* / Q000453:epidemiology / Q000821:virology; D017320:HIV Protease Inhibitors / Q000494:pharmacology*; D006801:Humans; D009154:Mutation / Q000187:drug effects; D063065:Organophosphonates / Q000494:pharmacology; D010349:Patient Compliance; D013449:Sulfonamides / Q000494:pharmacology; D000068698:Tenofovir; D014300:Trinidad and Tobago / Q000453:epidemiology
chemical_list: D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D063065:Organophosphonates; D013449:Sulfonamides; D000068698:Tenofovir; D000225:Adenine; D000069454:Darunavir